|
Giant Cell Glioblastoma
|
0.510 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate, that in addition to the histological and immunohistochemical evaluation, investigation of MGMT promoter methylation and in particular BRAF V600E mutations represent reliable additional tools to sustain differentiation of gcGBM from PXA on a molecular basis.
|
27253461 |
2016 |
|
Brain Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Recently, aberrant methylation of MLH1, MGMT and MSI were shown to be associated with mutations in genes such as BRAF, RAS and IDH1 in colon and brain tumours.
|
23414134 |
2013 |
|
Brain Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Surveillance, Epidemiology, and End Results (SEER) registries currently collect data on specific required factors related to brain tumors as defined by the American Joint Commission on Cancer, including World Health Organization (WHO) grade, MGMT methylation and 1p/19q codeletion status.
|
27418206 |
2016 |
|
Brain Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
We found a significantly increased frequency of G:C to A:T mutations of the p53 gene in brain tumors having a methylated MGMT promoter compared with those having an unmethylated MGMT promoter (P < 0.05), and all the non-CpG dinucleotide G:C to A:T mutations of p53 were in samples with a methylated MGMT promoter.
|
12503076 |
2003 |
|
Brain Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We found a significantly increased frequency of G:C to A:T mutations of the p53 gene in brain tumors having a methylated MGMT promoter compared with those having an unmethylated MGMT promoter (P < 0.05), and all the non-CpG dinucleotide G:C to A:T mutations of p53 were in samples with a methylated MGMT promoter.
|
12503076 |
2003 |
|
Brain Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
By removing alkyl groups from the O6-position in guanine, MGMT can prevent G:C to A:T transition mutations, a type of variation frequently involving TP53 mutations in brain tumors.
|
15450401 |
2004 |
|
Brain Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, IFNB) genes and lack of O6-methylguanine-DNA methyltransferase (MGMT) expression.
|
1501894 |
1992 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Methylation of the MGMT promoter correlated with better PFS and OS after GKS for recurrent GBM.
|
28536992 |
2017 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients.
|
31632497 |
2019 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There is no consensus recommendation regarding the best available treatment for patients over age 70 with glioblastoma; however, multiple studies have shown molecular characterization of glioblastoma in this group-particularly MGMT promoter methylation status-to be valuable in treatment decision making.
|
28620898 |
2017 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The pathological diagnosis was glioblastoma (GBM) with unmethylated O-6-methylguanine-DNA methyltransferase promoter and wild isocitrate dehydrogenase 1 gene.
|
23053494 |
2013 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The standard deviation (SD) of rCBV was significantly higher in glioblastoma (GBM) with methylated O6-methylguanine DNA methyltransferase (MGMT; 1.99 ± 0.73; p = 0.001) than in those with unmethylated MGMT (1.20 ± 0.45).
|
29468261 |
2019 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although this data is from a retrospective analysis using small number of patients, the study might indicate that concomitant use of temozolomide with radiotherapy is a crucial step in the standard treatment for glioblastoma patients with MGMT promoter methylation.
|
23377829 |
2013 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Carriage of the T allele was associated with a significantly elevated risk of developing glioblastoma (adjusted odds ratio, 1.96; P = .013), increasing further when glioblastoma was classified by the presence of MGMT methylation (adjusted odds ratio, 2.86; P = .001).
|
25910840 |
2015 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical data (age, sex, extent of surgical resection), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and pre-operative T2WI of 113 pathologically confirmed glioblastoma patients (from our institution, n = 61; from the Cancer Imaging Archive, n = 52) were retrospectively reviewed.
|
31150499 |
2019 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
On the other hand, glioblastomas with unmethylated MGMT promoters exhibited a wide range of MGMT mRNA expression.
|
22674304 |
2012 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We discovered that RARRES1 is highly expressed in patients with mesenchymal subtype, unmethylated MGMT, IDH1 wild type, and non-G-CIMP, all of which are molecular characteristics of malignant GBM.
|
31632537 |
2019 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme.
|
21528672 |
2011 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
55 glioblastomas were investigated for MGMT methylation status using methylation-specific multiplexed ligation probe amplification (MS-MLPA), illumina human methylation 450K BeadChip array (HM450 K) analysis, and compared to MGMT protein expression by immunohistochemistry (IHC) staining.
|
26289551 |
2016 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pseudoprogression (PsP) occurs at a higher rate in glioblastoma multiforme with a methylated MGMT promoter-a subset with increased sensitivity to chemoradiotherapy and better overall prognosis.
|
24285548 |
2014 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We applied real-time semi-quantitative methylation-specific polymerase chain reaction (SQ-MSP) of the MGMT gene promoter region to 84 glioblastoma patients.
|
29963232 |
2018 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The methylation status of the methylguanine methyltransferase (MGMT) promoter has been associated with treatment response in glioblastoma.
|
24949678 |
2014 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Glioblastoma (51.52%) was the commonest astrocytic tumor with 74.67% of them being isocitrate dehydrogenase 1 (IDH1) negative and 41.38% with O (6)-methylguanine DNA methyltransferase (MGMT) promoter methylated.
|
29730791 |
2018 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.
|
15758010 |
2005 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
|
19514084 |
2009 |